When was Denali Therapeutics founded?

Denali Therapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Denali Therapeutics located?

Denali Therapeutics is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Denali Therapeutics?

Ryan Watts of Denali Therapeutics.

How many employees does Denali Therapeutics have?

As of Sep 30, 2026, the latest employee count at Denali Therapeutics is 601.

Is Denali Therapeutics a funded company?

Denali Therapeutics is a funded company, having raised a total of $347M across 3 funding rounds to date. The company's 1st funding round was a $217M Series A round, raised on May 14, 2015.

When was the latest funding round of Denali Therapeutics?

Denali Therapeutics' latest funding was a $500M Post IPO round on Feb 27, 2024, with participation from 0 investor.

What is the annual revenue of Denali Therapeutics?

Annual revenue of Denali Therapeutics is between $100M and $500M as on Dec 31, 2023

Is Denali Therapeutics a Neurology company?

The primary sectors of Denali Therapeutics are Neurology and Gastroenterology.

Where does Denali Therapeutics rank among its competitors?

Denali Therapeutics ranks 1st amongst 476 active competitors, of which 170 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Denali Therapeutics?

Denali Therapeutics' top competitors include Fulcrum Therapeutics, Annexon and Regenxbio. Among them, Alchemab secured the most recent funding round in July, 2026.

Denali Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Denali Therapeutics is a public company based in San Francisco (United States), founded in 2015 by Ryan Watts, Marc Tessier Lavigne and Alexander Schuth. It operates as a Developer of therapies to treat neurodegenerative diseases. Denali Therapeutics has raised $347M in funding. The company has 476 active competitors, including 170 funded and 86 that have exited. Its top competitors include companies like Fulcrum Therapeutics, Annexon and Regenxbio.

Sectors and market segments that Denali Therapeutics operate in

Denali Therapeutics serves in the Life Sciences market segments.The primary business model of Denali Therapeutics are:

Company Details

Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.

Website: www.denalitherapeutics.com/
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Public

Total Funding

$347M in 3 rounds

Latest Funding Round

Post IPO, Feb 27, 2024, $500M

Investors

Foresite Capital & 11 more

Ranked

1^st among 476 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2023

Employee Count

601 as on Sep 30, 2026

Investment & Acquisitions

Triller

Similar Companies

Fulcrum Therapeutics & 585 more

Exit Details

Public

View Denali Therapeutics' full profile

Denali Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Denali Therapeutics Inc. CIN: 1714899 , United States, Active	Oct 13, 2013	$100M - $500M (As on Dec 31, 2023)	-	-
DENALI THERAPEUTICS, INC. CIN: 463872213 , United States, Active	Dec 31, 1999	-	410 (As on Dec 31, 2024)	-

Denali Therapeutics got listed on Dec 08, 2017.

Click here to take a look at Denali Therapeutics's IPO in detail

Denali Therapeutics has raised a total funding of $347M over 3 rounds. Its first funding round was on May 14, 2015. Denali Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of Denali Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 27, 2024	$500M	Post IPO	-	-	-	-
Aug 25, 2016	$130M	Series B	-	-	-	Baillie Gifford, Arch Venture Partners, F-Prime Capital, Alaska Permanent Fund, Flagship Pioneering
May 14, 2015	$217M	Series A	-	-	-	Arch Venture Partners, F-Prime Capital, Alaska Permanent Fund, Flagship Pioneering

Access funding benchmarks and valuations. Sign up today!

View details of Denali Therapeutics's funding rounds and investors

The founders of Denali Therapeutics are Ryan Watts, Marc Tessier Lavigne and Alexander Schuth.

Here are the details of Denali Therapeutics' key team members:

Ryan Watts: Co-Founder & CEO of Denali Therapeutics.
Contact Info: 1 email address
Marc Tessier Lavigne: Former Co-Founder of Denali Therapeutics.
Contact Info: 1 email address
Alexander Schuth: Co-Founder, Chief Operating and Financial Officer of Denali Therapeutics.
Contact Info: 2 email addresses

View details of Denali Therapeutics's Founder profiles and Board Members

Denali Therapeutics' employee count trend

Denali Therapeutics has 601 employees as of Sep 26. Here is Denali Therapeutics's employee count trend over the years:

Employee count trend for Denali Therapeutics

Uncover Denali Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Denali Therapeutics include Fulcrum Therapeutics, Annexon and Regenxbio. Here is the list of Top 10 competitors of Denali Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	74/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
7th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
8th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
10th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Denali Therapeutics's competitors? Click here to see the top ones

Denali Therapeutics has acquired Triller. Denali Therapeutics has not made any investments as of now.

Here is the latest report on Denali Therapeutics's sector:

Free

Neurology - Sector Report

Edition: August, 2026 (73 Pages)

View all reports related to Denali Therapeutics

Media has covered Denali Therapeutics for a total of 23 events in the last 1 year, 12 of them have been about company updates and 1 about partnerships.